Acute Coronary Syndrome (ACS)
Conditions
Interventions
Experimental Group:Qi Shen Yi Qi Dropping Pill
Control Group:Placebo
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)Meets the diagnostic criteria for Acute Coronary Syndrome (ACS). (2)Aged between 18 and 80 years. (3)IL-1ß levels greater than 3 pg/mL. (4)The patient and their family have agreed to the treatment plan and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with severe structural heart disease; (2) Patients with severe underlying diseases such as liver or renal system disorders, including those with liver function (ALT or AST) greater than 1.5 times the upper limit of normal, or renal dysfunction; (3) Patients with other systemic diseases that affect coagulation or immune function (e.g., hematologic disorders, autoimmune diseases, malignancies, etc.); (4) Patients who have had an acute infection or acute exacerbation of other diseases within the past two weeks, such as hypertensive emergencies; (5) Pregnant or lactating women, or women who may become pregnant during the study period; (6) Patients with a history of allergic reactions or hypersensitivity to any components of the investigational drug; (7) Patients who have taken other traditional Chinese medicines or Chinese patent medicines in the past three months, or those who have used medications that may affect coagulation or immune function; (8) Patients who have received other investigational drugs within three months prior to the administration of the study drug, or within five half-lives of other investigational drugs (whichever is longer); (9) Patients with psychiatric, psychological, or other conditions that are incompatible with the completion of the study; (10) Patients who are deemed unsuitable for clinical trials for other reasons as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin-1 beta (IL-1ß);hs-CRP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Monocyte subtypes;Seattle Angina Questionnaire (SAQ);Inflammatory Hematological Ratio; | — |
Countries
China
Contacts
Public ContactLi Xianlun
China-Japan Friendship Hospital
Outcome results
None listed